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Abstract 
 
The panel of serologic markers for inflammatory bowel diseases (IBD) is rapidly 
expanding. Anti–Saccharomyces cerevisiae antibodies (ASCA) and atypical perinuclear 
antineutrophil cytoplasmic antibodies (P-ANCA) remain the most widely investigated; 
however there are methodological difficulties and no clear guidelines for 
immunofluorescence detection and interpretation of ANCA patterns in IBD hampering 
the diagnostic potential of the test. Increasing amount of experimental data is available 
on newly discovered antibodies directed against various microbial proteins and 
carbohydrates. Such antibodies include anti-OmpC (outer membrane porin C), anti-
Pseudomonas fluorescens (anti-I2), anti-flagellin antibody CBir1 and antiglycan 
antibodies (anti-laminaribioside carbohydrate antibody [ALCA], anti-chitobioside 
carbohydrate antibody [ACCA], anti-mannobioside carbohydrate antibody [AMCA]). 
The pathogenic significance of these antibodies has not been established and it 
remains unclear whether they arise as a result of tissue damage, increased permeability or 
the mucosal immune perturbation seen in Crohn’s disease. Reactivity to microbial 
components was associated with NOD2/CARD15 genotype. Moreover, positive 
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correlation was found between the number of mutations and the prevalence of 
antimicrobial antibodies (gene dosage effect), further supporting the role of altered 
microbial sensing in the pathogenesis of Crohn’s disease. 
The role of the assessment of various antibodies in the current IBD diagnostic 
algorithm is often questionable due to their limited sensitivity. In contrast, the association 
of serologic markers with disease behaviour and phenotype is becoming increasingly 
well-established. An increasing number of observations confirm that patients with 
Crohn’s disease expressing multiple serologic markers at high titers are more likely to 
have complicated small bowel disease (e.g. stricture and/or perforation) and are at higher 
risk for surgery than those without, or with low titer of antibodies (serology dosage 
effect). Creating homogenous disease sub-groups based on serologic response may help 
develop more standardized therapeutic approaches and may help in a better 
understanding of the pathomechanism of inflammatory bowel diseases. Further 
prospective clinical studies are needed to establish the clinical role of serologic tests in 
IBD. 
 
Keywords: serologic markers, inflammatory bowel disease, ulcerative colitis, Crohn’s 
disease, indeterminate colitis. 
 
 
Introduction 
 
Serologic response to various microbial and autoantigens can develop in inflammatory 
bowel diseases (IBD). In addition to the well-established atypical perinuclear antineutrophil 
cytoplasmic antibodies (atypical P-ANCA) and anti–Saccharomyces cerevisiae mannan 
antibodies (ASCA), a number of the new antibodies have recently been discovered and data 
on their clinical significance has been rapidly increasing. 
The usefulness of different antibodies in Crohn’s disease (CD) and ulcerative colitis 
(UC) as diagnostic markers, follow-up parameters, or as subclinical markers in affected 
families has been actively investigated. Another field of interest is the association of the 
serologic markers with the disease phenotype, disease course, and treatment stratification. 
The role of the antibodies in disease pathophysiology remains to be fully elucidated. 
In this review we discuss current understanding on the clinical importance of various 
established and newly recognized serologic markers in IBD. 
 
 
Serologic Panel for  
Inflammatory Bowel Disease (IBD) 
 
Anti-Neutrophil Cytoplasmic Antibody (ANCA) 
 
The classic ANCA tests are used to diagnose and monitor the inflammatory activity in 
primary small vessel vasculitides. On the basis of an international consensus statement, 
ANCA testing is performed with serum samples by indirect immunofluorescence (IIF) on 
normal peripheral blood neutrophils. Two basic ANCA patterns are detectable: the 
cytoplasmic (C-ANCA) and the perinuclear (P-ANCA). The C-ANCA pattern appears as a 
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granular, diffuse cytoplasmic fluorescence, often with accentuated fluorescence around the 
nuclear lobes. Typical P-ANCA reactivity results in homogeneous rim-like staining of the 
perinuclear cytoplasm. ANCA positive serum samples and also those with any other 
cytoplasmic fluorescence or an antinuclear antibody (ANA) that results in homogeneous or 
peripheral nuclear fluorescence should be tested in enzyme-linked immunosorbent assays 
(ELISA) for proteinase 3 (PR3) and myeloperoxidase (MPO) antibodies, because these are 
the most common of targets of C-ANCA and P-ANCA antibodies respectively (minimum 
recommendation of consensus group). Optimally, ELISAs should be performed on all serum 
samples, since IIF alone detects only 90% to 95% of all ANCA positive serum samples in 
patients [1]. A third ANCA pattern of clinical importance is the so-called atypical P-ANCA 
staining. It has been suggested that since the target antigens of atypical P-ANCA are nuclear 
rather than cytoplasmic, this pattern would be more properly named ANNA (anti-neutrophil 
nuclear antigen). Until the target of atypical P-ANCA reactivity is identified however, it is 
likely that the atypical nomenclature will remain in common use. Atypical P-ANCA is 
recognized as a broad inhomogeneous rim-like staining of the nuclear periphery often with 
multiple intranuclear foci [2]. The antigen specificity of these atypical ANCAs are different 
from the classic C-and P-ANCAs, being localized in the nuclear periphery, in contrast to the 
cytoplasmic location of the classic C- and P-ANCAs. Atypical P-ANCA are most commonly 
seen in patients with IBD, especially UC, and some autoimmune liver diseases such as 
autoimmune hepatitis (AIH) and primary sclerosing cholangitis (PSC). 
Atypical P-ANCA is present in the sera of 40% to 80% of patients with UC [3,4] and to a 
lesser extent in CD (5-25%) [5]. The prevalence of the antibody is also high in patients with 
PSC (88%) [6] and AIH type I (81%) [7], but is detected in only 1-3% of healthy control 
subjects. Some sera with atypical ANCA reactivity are positive for antibodies to elastase, 
lactoferrin, cathepsin G, lysosyme or bactericidal permeability-increasing protein [BPI]), but 
since they are only detected in a few atypical P-ANCA positive sera, these antigens do not 
appear to be the primary targets of atypical P-ANCA reactivity [8]. The target antigen(s) of 
atypical P-ANCA have not been definitively identified. What is in agreement is that target 
antigen(s) are associated with inner side of the neutrophil nuclear membrane. A 50-kilodalton 
myeloid-specific protein has been identified by Terjung and appears to be the best current 
candidate as the primary target of atypical P-ANCA[2].Histone H1, which binds to the DNA 
linking nucleosomes, has been suggested as a target antigen of atypical P-ANCA [9]. 
However, histone H1 is found in all cells with nucleus and is not specific to neutrophils. 
There has been little independent support of this idea. More recently, the proposed anti-α-
enolase antibodies were present in a substantial proportion of patients with IBD but also in 
various inflammatory/autoimmune disorders, and non-IBD gastrointestinal controls. And no 
association was found between the presence of anti-α-enolase antibodies and the P-ANCA 
status of patient with IBD. Absorption with α-enolase before IIF did not eliminate the P-
ANCA staining pattern, which is consistent with the idea that α-enolase is not the target 
antigen of P-ANCA [10]. Since the exact target antigen(s) of atypical P-ANCA has not been 
identified, there are currently no sensitive and specific solid-phase assays available to screen 
for these antibodies. The IIF is the only widespread method to detect the antibodies; however 
it is technically demanding, subjective, and requires experienced observers for good 
interpretation. Unlike the Consensus Recommendations for the vasculitis-associated ANCAs, 
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there are no clear guidelines for immunofluorescence detection and interpretation of atypical 
P-ANCA patterns. A reproducible and specific method was described by Terjung et al, who 
used the combination of ethanol-fixed and formalin-fixed human neutrophil substrates do 
discriminate between P-ANCA and atypical P-ANCA. Using the cross-linking fixative 
formalin, typical P-ANCA diffusely labeled the cytoplasm, that is, converted to cytoplasmic 
ANCA pattern. In contrast, sera containing atypical P-ANCA produced a fine ‘perinuclear’ 
labeling with multiple intranuclear fluorescent foci. This pattern, however, was obvious only 
with confocal laser scanning microscopy [11]. When lower resolution planar indirect 
immunofluorescence microscopy is used, this labeling is difficult to detect, and therefore the 
fluorescence is usually considered negative[12, 13]. However, simultaneous reactivity of 
atypical P-ANCA on formaldehyde- and ethanol-fixed neutrophils and the feasibility of the 
new microscopic criteria have not been systematically studied in IBD. Most studies dealing 
with serological evaluation of IBD use ethanol-fixed neutrophils only, rendering them biased 
by MPO-ANCA, antinuclear antibodies (ANA) and other, non-IBD associated antibodies 
(anti-lamin, anti-Golgi, anti-actin, etc. [14]). 
ANCA systems that replace formalin-fixed neutrophils with an enzyme (DNase I) 
digestion step during IIF were developed by Targan and colleagues [15], but rarely 
performed outside the group. Instead of the term “atypical”, they rather use “DNase-
sensitive” (i.e., not detectable on DNase-treated neutrophils) P-ANCA [16,17]. 
The poor agreement between various ANCA assays and different observers is well 
documented [18,19]. The remarkable differences are likely attributable to several distinctive 
parameters of the various manufacturer kits (differences in cell preparation affecting 
background fluorescence, fixation methodologies, buffers and conjugates). Discrepancies are 
further increased by different microscopes and the observers’ various experience level in 
inter-observer studies. 
In a recent study[8], in a group of 204 patients with IBD we attempted to differentiate 
among C-ANCA, P-ANCA and atypical P-ANCA based on the occurrence of the patterns on 
ethanol- and formalin-fixed slides and using predetermined IIF criteria. The most often 
detected ANCA pattern was atypical P-ANCA both in UC and CD patients. However, we 
found a significant variation in the occurrence of atypical P-ANCA in the sera of patients 
with UC (9.4-39.6%) and CD (9.3-16.7%) among different, commercially available ANCA 
assays (INOVA, IMMCO, Immunoconcepts, Euroimmun). All possible pair-wise 
comparisons demonstrated a statistically significant lack of agreement between the ANCA 
assays (κ: 0.14-0.34). Similar results were published in two earlier studies. Joossens et al[18] 
assayed the presence of ANCAs by four different, commercially available substrates (Bio-
Rad, The Binding Site, Immunoconcepts, and INOVA) in 50 UC patients. The prevalence of 
atypical P-ANCA varied between 16% and 62% using both ethanol- and formalin-fixed 
human neutrophil substrates, with κ values < 0.2 indicating poor agreement. In the paper of 
Sandborn et al[19], the sensitivity for P-ANCA detection in 162 IBD patients varied between 
0% and 63% in different laboratories (Prometheus, Oxford, Wuerzburg, Mayo, and Smith 
Kline Beecham). One of the assays in this study used the DNase digestion method, while the 
others only used ethanol-fixed slides. 
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In the inter-observer study, we found better concordance for atypical P-ANCA (κ=0.44), 
suggesting that the differences between IIF ANCA assays from various sources contributed 
more to the discrepancies than the type of the microscope or the observers’ experience. These 
values are in accordance with our previously published observation on the prevalence of P-
ANCA in IBD [20]. 
The overall specificity of the atypical P-ANCA is 84-95%, sensitivity is 48-63%, positive 
predictive value (PPV) is 69%, and negative predictive value (NPV) is 89%[5]. 
ANCA production in UC appears to be genetically conditioned by promoter 
polymorphism of both anti- and proinflammatory cytokine molecules. The high producer 
TNF-α genotype clearly correlated with ANCA positivity as well as the low producer IL-10 
genotype. Furthermore, combination of both genotypes had a greater influence on ANCA 
positivity than each individual genotype. One possible explanation would be that the 
incremented local synthesis of TNF-α that cannot be counterbalanced by a low production of 
IL-10 in patients may create a microenvironment in which autoimmune inflammatory 
response would tend to perpetuate [21]. 
 
 
Anti–Saccharomyces Cerevisiae Antibodies (ASCA) 
 
ASCA are antibodies directed primarily against a 200 kDa- phosphopeptidomannan cell 
wall component of the common baker’s or brewer’s yeast Saccharomyces (S.) cerevisiae 
[22]. ASCA reactivity could be a result of cross-reacting antibodies to antigens found in a 
non-yeast organism and has not yet been identified [23,24]. Mannose is not only found in 
yeast but also in mycobacteria and other microorganisms [25]. Both IgA and IgG antibodies 
are formed. Separate and polyvalent ELISA configurations are available for ASCA IgG and 
IgA detection. ASCA are more frequently found in CD patients (50-80%) compared to 
patients with UC (2-14%) and to normal healthy subjects (1-7%) [26,27]. Approximately 
two-thirds of the CD patients with ASCA IgG are also positive for ASCA IgA, but from 0 to 
19% of the patients have only ASCA IgA antibodies. This suggests that both ASCA IgG and 
IgA antibodies should be measured. In CD, up to 90% specificity has been reported in 
specimens positive for both ASCA IgG and IgA antibodies, especially when the magnitude of 
both the IgG and IgA ASCA antibodies is high [28]. Sensitivity of ASCA testing ranges from 
41- 76%, PPV 88% and NPV 68% [29]. More recently a large number of IBD and control 
sera, previously tested for ASCA, were used for evaluating a new antisynthetic 
oligomannoses antibody (AΣMA) test by Vandewalle-El Khoury et al. AΣMA revealed the 
heterogeneity of the antioligomannose antibody response in CD patients and increased the 
sensitivity of CD diagnosis when combined with ASCA. Of the ASCA negative CD patients 
25% were positive for AΣMA [30]. 
ASCA IgG and IgA levels in CD patients are highly variable[28]. The prevalence of 
ASCA is much higher in cases of sporadic CD and in families with only CD (63%) compared 
to families with both CD and UC (33%). The familial trait to ASCA is obvious, but it is 
questionable whether this is due to the genetic background or environmental agents effect in 
the childhood predisposing to the disease susceptibility. 
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A comparative study revealed a wide range in sensitivities and specificities among four 
assays, mainly as a consequence of the cut-off values chosen. Sensitivity was inversely 
related to specificity and PPV. Results correlated well overall and the different ROC curves 
showed good agreement [31] We also compare the clinical accuracy of gASCA IgG and 
conventional ASCA IgG in a total of 652 IBD patients. The performances of the two IgG test 
were similar. The weighted Kappa coefficients (κ) suggested good concordance between the 
two assays (κ: 0.67, p<0.0001). gASCA and ASCA IgG positivity were observed in 50.4% 
and 50.6% CD patients, respectively. The combined positivity rate was 58.9%. Both tests 
identified 83.5% of the same patients; however, 8.4% and 8.3% of all patients were identified 
only by one of the tests. This suggests that while the antigens used in the two assays are 
similar, they also contain different non-overlapping epitopes  [32]. 
 
 
Newly Discovered Serologic Markers 
 
Anti-OmpC antibody is directed against the outer membrane porin C transport protein of 
the Eschericia coli. The detection of the IgA antibody is done with ELISA. Anti-OmpC has 
been reported in 24-55% of CD patients [33,34]. The prevalence of anti-OmpC was 
insignificant in UC patients and in healthy subjects (5-11% and 5%, respectively). However, 
others reported higher occurrence of this antibody both in UC and healthy controls using 
another commercially available OMP ELISA test [20, 35]. Anti-OmpC maybe of value to aid 
diagnosis of ASCA negative CD patients. The prevalence of anti-OmpC among ASCA 
negative patients is 5-15%. 
A fragment of bacterial DNA (I2), a homolog of the tetR bacterial transcriptional factor 
family, has been identified from lamina propria mononuclear cells in active CD and shown to 
be associated to Pseudomonas fluorescens  [36,37]. IgA anti-I2 antibody has been detected by 
ELISA in IBD patients with a seroprevalance of 54% in CD and 10% in UC. Anti-I2 
antibody was also found in patients with other inflammatory enteritis (19%) and also in 
healthy subjects (4%)[5]. 
Serologic expression cloning was used by Lodes et al. to identify commensal bacterial 
proteins in colitic mice. The dominant antigens were found to be flagellins. Strong B-cell and 
CD4+ T-cell responses were observed against one of these flagellins (anti-CBir1). Colitis 
was induced when the T-cell line specific for CBir1 was transferred into naive severe 
combined immunodeficient mice. Approximately 50% of patients with CD have IgG serum 
reactivity to CBir1 versus 6% of UC patients and 8% of healthy subjects. CBir1 is the first 
bacterial antigen to induce colitis in animal models of IBD and also leads to a pathological 
immune response in IBD patients [38]. Among the population of CD patients positive for 
atypical P-ANCA, but who do not react to other known antigens, 40-44% are positive for 
anti-CBir1 whereas the antibody has only been found in only 4% of atypical P-ANCA 
positive UC patients. Serum responses to CBir1 maybe of help in differentiation between 
atypical P-ANCA positive CD and UC patients independently of ASCA [39,40]. 
Anti-pancreatic autoantibodies (PAB) are directed against the exocrine pancreatic tissue 
[41]. The exact target antigen(s) however, have not yet been identified. The detection of PAB 
is done by IIF on human or primate pancreas substrate and the reported prevalence in small 
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scale studies was 27–39% in CD patients compared to 0-5% of UC patients and 0-8% of 
healthy subjects [42,43,44,45]. Based on these results PABs have been suggested to be highly 
specific for CD. However, a more recent study from Belgium found a much higher 
prevalence (22.2%) of PAB in UC [46]. The occurrence of PAB was similar to the above 
mentioned data in our IBD cohort which is the largest known patient group so far (CD= 579, 
UC=110). The autoantibody was specific for CD (92-95%), while sensitivity alone was only 
38-41%, albeit the same PAB prevalence was found in celiac disease at the diagnosis than in 
UC (23.3% vs. 22.7%) (unpublished results). The relevance of PAB in the pathogenesis of 
CD is unclear and whether the presence of PAB identifies a CD subgroup also remains to be 
determined [47]. 
Earlier studies showed great variation in the frequency of goblet cell antibodies in IBD 
(0%-40%)[45, 48,49] and found these autoantibodies as specific markers to UC. In these 
studies, tissue samples from other species, for example monkey or intestinal goblet cell 
culture were used. More recently Ardesjo et al [50] reported that 84% of IBD patients, both 
UC and CD, have antibodies against goblet cells in the human appendix substrate. The 
specificity of goblet cell antibodies in this study was high (92%) for distinguish IBD patients 
from healthy controls but lower (50-60%) when comparing IBD to the control gastrointestinal 
inflammatory diseases. However the staining pattern was different and its intensity was 
weaker in celiac disease and infectious gastroenteritis as compared to IBD patients 
suggesting different goblet cell antigens. The results of this study propose that 
immunoreactivity against goblet cells may be of importance in the pathogenesis of IBD 
however identification of goblet cell antigens is mandatory. 
Patients with CD express antibodies to cell wall carbohydrate epitopes found in different 
micro-organisms, immune cells, erythrocytes, and tissue matrices. Using a glycan array 
(GlycoChip) and ELISA, in addition to antibodies against mannan (anti-covalently attached 
mannan from Saccharomyces cerevisiae IgG antibodies or gASCA) other anti-glycan 
antibodies have been found including anti-mannobioside [(Man(α1,3)Man(α) carbohydrate 
IgG antibody or AMCA], antibodies against laminaribioside [anti-laminaribioside 
(Glc(β1,3)Glc(β)) carbohydrate IgG antibodies or ALCA, a building block of laminarin, 
which may be found in the cell walls of saprophytic and pathogenic fungi and yeast] and 
chitobioside [anti-chitobioside (GlcNAc(β1,4)GlcNAc(β)) carbohydrate IgA antibodies or 
ACCA, a component of chitin, a major element of the insect cuticle and cell walls of 
infectious pathogens such as bacteria and yeast] [51]. 
The positivity rate was 15-18% for ALCA, 11-21% for ACCA and 12-28% for AMCA in 
two large, independent cohort from Western [35] and Eastern-Europe[32]. Interestingly, the 
positivity rate was somewhat higher in a study from Israel in both the initial and the validated 
CD cohorts [52]. However, we must note that AMCA was not measured and the total patient 
number in the latter study was relatively small, which may at least partly contribute to the 
heterogeneity observed among these studies. In generally, these anti-glycan markers were 
highly specific for CD, but their sensitivities were poor. 
Comparing all 4 anti-glycan antibodies’ performance to the results of the combined IgG 
or IgA ASCA, we found that both panels identified 59.4% of all CD patients. These data 
suggests that there is no advantage of using anti-glycan markers instead of traditional ASCA 
IgG and A, not to mention the additional cost. Nonetheless, the two panels identified the 
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same patients in only approximately 80% of the cases, while 10.8% of all patients were 
identified only by the two conventional ASCA tests and another 10.8% by anti-glycans. 
Either of the two panels was positive in 70.2% of CD patients. 
 
 
The Diagnostic Value of the Serologic  
Markers in IBD 
 
The role of atypical P-ANCA and ASCA as diagnostic markers for IBD appears to be 
limited because of their moderate sensitivity and presence in other conditions. It must be 
emphasized that neither ASCA, nor atypical P-ANCA negativity rules out IBD. Similarly, the 
presence of these antibodies does not confirm the diagnosis of IBD. Atypical P-ANCA can 
also be observed in other colitis, e.g. collagenous or eosinophilc colitis and in various 
autoimmune liver diseases such as AIH and PSC [53,54] ASCA has been found in 
autoimmune hepatitis (20%) and gastrointestinal disorders such as celiac disease [55]. The 
frequency of ASCA at diagnosis of the celiac disease varied from 27% to 59% in the different 
studies owing to the differences in the number and the age of the patients as well as the 
commercial assays used for antibody detection [56,57,58,59,60]. The higher frequency of 
ASCA positivity has also been reported in adult celiac cohorts compared to the pediatric ones 
supposedly due to the longer gluten exposition and therefore bearing more lingering gut 
mucosal damage. In the majority of patients, ASCAs disappeared during sufficiently long-
lasting gluten free-diet (GFD). However, in children the disappearance of ASCA positivity 
has been more pronounced attributed to the well-known fact that gut permeability normalizes 
much better in children than in adults. In addition to ASCA, our group also found anti-glycan 
and anti-OMP antibody frequencies significantly higher in celiac patients at diagnosis. 
Positivity for these antibodies were completely lost after adherent long-standing GFD[61]. 
The combination of atypical P-ANCA and ASCA however, may be of help in patients in 
whom distinction between CD and UC is not obvious with the classic diagnostic tools 
(patient history, radiologic examination, endoscopy and biopsy). The ASCA+/ atypical P-
ANCA- serologic pattern is mainly characteristic of CD, while the ASCA-/ atypical P-ANCA+ 
is characteristic of UC. Several independent studies found that these combinations had 
sensitivities of from 30% to 64%, specificity more than 90%, and PPV from 77% to 96% [15, 
26,27,62,63]. 
The difficulty in the clinical differentiation between CD and UC, however, lies in 
distinguishing isolated colonic CD from UC, as ileal and proximal small-bowel involvement 
occurs only in CD. ASCA IgA and IgG double positivity (PPV for CD: 83%), 
pANCA+/ASCA- (PPV for UC: 80%) and pANCA-/ASCA+ pattern (82%) were associated 
with reasonable positive predictive values, nonetheless the sensitivity was low. Including 
Omp in the analysis had no additional value and resulted in even lower sensitivity and 
specificity values [20]. ASCA in combination with PAB autoantibodies also increases the 
sensitivity to detect isolated colonic CD. 
Serologic evaluation may be of help in patients with indeterminate colitis (IC) to increase 
the diagnostic accuracy. Ninety-seven patients with IC were enrolled, analyzed for atypical 
P-ANCA and ASCA, and followed up prospectively in a multicentre study of Joosens et 
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al.[64]. After the 1-year follow-up, a definitive diagnosis was reached in 31 of 97 patients 
(37%). In IC patients, ASCA+/ atypical P-ANCA- results correlated with CD in 80%, whereas 
ASCA-/ atypical P-ANCA+ correlated with UC in 63%. The remaining ASCA-/ atypical 
ANCA+ patients were eventually determined to be CD, but clinically showed a UC-like CD 
phenotype. Remarkably, during the 9.9 yr follow-up, 48.5% of the patients did not show 
antibodies against ASCA or atypical P-ANCA. In 85% of these seronegative patients the 
diagnosis remained indeterminate. In contrast, 48% of the seropositive patients became CD or 
UC on follow-up. Adding anti-OmpC and anti-I2 to the serologic panel in patients with IC 
did not add diagnostic clarification [65]. 
Several groups have studied whether atypical P-ANCA and ASCA are subclinical 
markers of IBD in families. Some studies [66,67] showed that presence of atypical P-ANCA 
occurred frequently in healthy first-degree relatives of UC patients, whereas other studies 
were not able to confirm this observation [68,69]. ASCA positivity was obviously found at a 
higher rate in unaffected first-degree relatives of CD patients than in the general population 
(20-25% vs. 5%) [70,71]. More recently, increased anti-OmpC expression in the unaffected 
family members of CD patients were reported providing evidence that anti-OmpC is a 
familial trait that appears to be determined by genetic factors. Moreover, there were increased 
level of serum expression in unaffected relatives compared with healthy controls even in 
those individuals with expression falling within normal range, thus underscoring the fact that 
seroreactivity to microbial antigens is a quantitative trait [72]. 
Israeli et al [73] demonstrated that the presence of ASCA and atypical P-ANCA in 
healthy subjects can predict for IBD before the emergence of overt clinical manifestations. 
Serum samples were obtained systematically and stored from 5% of all military recruits. 
ASCA were detected in 31% of CD patients before clinical diagnosis. The mean interval 
between ASCA detection and diagnosis was 38 months. There was no ASCA positivity in 
control population. Atypical P-ANCA was present in 25% of patients with available sera 
before the diagnosis of UC. None of their 24 matched controls were positive. 
 
 
Association with Disease Phenotypes  
and Progression 
 
The occurrence of atypical P-ANCA in UC is associated with a characteristic clinical 
appearance and represents a distinct subgroup which is often characterized by specific HLA 
markers. These patients have a higher probability to develop a severe left-sided ulcerative 
colitis, which is more resistant to treatment than the usual case. The disease has a more 
aggressive course requiring surgery earlier in the course of the disease [74]. Some authors 
suggest that pouchitis develops more frequently after ileal pouch anastomosis [75], whereas 
others were not able to confirm this observation. The presence of atypical P-ANCA identifies 
a subgroup of CD patients characterized by “UC-like” colitis; the inflammation usually 
involves the left side of the colon and the response to therapy is generally good [55]. We 
could not confirm these findings. In our study patients with CD, who were atypical P-ANCA-
positive, had no particular clinical features compared with patients who were P-ANCA-
negative. Furthermore, the serological profile did not predict disease phenotype in UC [20]. 
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The atypical P-ANCA in CD patients associated with later age of onset and a relative 
decreased incidence of complications such as stricture and/or perforation [76,77]. 
Since earlier cross-sectional study of Vasiliauskas et al.[16], several authors found 
consistently that phenotype and the disease course of CD are heavily dependent on the 
presence and extent of the serologic response targeted against various microbial antigens in 
multiple geographically distinct CD cohorts. In patients with a ASCA+ (IgG and/or IgA)/ 
atypical P-ANCA- phenotype, small bowel involvement (with or without colonic disease) is 
more typical than the pure colonic disease (68-76% vs. 34-46%)[20, 27, 78,79]. ASCA 
positivity predicts a more aggressive disease course with a higher rate of complications. 
ASCAs have been associated with stricturing and penetrating type of disease as opposed to 
the inflammatory one and a higher risk of small bowel resection[16, 20, 74, 80]. Several 
studies suggest that ASCA positivity is associated with an earlier onset of disease[16, 20, 25]. 
ASCA IgA positivity in children may represent a higher risk for relapses (OR 2.9 [95%CI 
1.33-6.33]) [81] 
The presence of anti-OmpC in adult CD patients is associated with an increased 
prevalence of the penetrating form only [33, 39, 80, 82] while in children both the penetrating 
and stenosing forms [83] are more frequent. Moreover, antibody positivity may lead to a 
more aggressive course of disease and a higher risk for surgical interventions. 
Like ASCA and anti-OmpC, anti-I2 also appears to be associated with an increased risk 
for complications in adult CD patients. It is an independent risk factor for the development of 
the stenosing form and the need for surgical interventions [33, 39, 80, 82]. 
The number of antibodies produced against these microbial antigens in CD shows a 
positive correlation with the severity of the disease course (“serology dosage effect”). Mow et 
al.[80] analyzed 303 patients retrospectively and found that simultaneous presence of 3 
antibodies (ASCA, anti-OmpC and anti-I2) results in an increased risk of complications 
(stenosing form [72% vs. 23%], penetrating form [58.7% vs. 27.9%]) and need for surgical 
intervention [72% vs. 23%]), as compared to the seronegative group. When all three 
antibodies are present, the OR is 8.6 (95%CI [4.0-18.9]). These findings were confirmed by a 
similar study in a Scottish CD cohort [82]. In addition to qualitative correlations, quantitative 
correlations with serologic responses to ASCA, anti-OmpC, anti-I2 are also present. Patients 
expressing serologic markers at high titer are more likely to have complicated small bowel 
CD[80]. 
Recently, anti-CBir1 antibody has been added to the armamentarium of available 
serologic markers that can be measured. Two studies[39, 40] demonstrated that the anti-
CBir1 antibody is associated with ileal involvement in adult CD patients independently from 
other serologic markers, and it predisposes for the development of both stenosing and 
penetrating forms. 
These findings were largely corroborated by two recent large scale studies[32, 35] 
examining the association between a new set of antibodies directed against anti-glycans 
(gASCA, ALCA, ACCA, and AMCA) and a more universal antibody against anti-OmpC. 
The presences of these antibodies are closely related to a complicated disease phenotype and 
need for surgery. The number and the magnitude of serological response were also associated 
with ileal, non-inflammatory disease and the risk for surgery. 
The Utility of Serological Markers in Inflammatory Bowel Diseases 181
Studies evaluating disease associations with seroreactivity to microbial antigens are 
limited by different facts. Firstly, the ideal way to address this issue would be to study 
patients prospectively, early in the course of their disease before the development of 
complications. However, the above mentioned studies were cross-sectional ones representing 
IBD patients who have already developed (or not) certain disease complication [84]. We now 
have two 2 key studies in this regard [83, 85] confirming the findings in cross-sectional 
studies. In a prospective pediatric cohort (n=196) Dubinsky et al.[83] found that the presence 
and magnitude of immune responses to microbial antigens (ASCA, anti-OmpC, anti-I2 and 
anti-CBir1) early in the course of the disease [median 9.4 months postdiagnosis] are 
significantly associated with more aggressive disease phenotype. The risk of developing 
penetrating and/or stricturing CD was increased 11-fold in those individuals with immune 
responses to all four microbial antigens compared to seronegative cases (95%CI [1.5-80.4]). 
Moreover, they demonstrated that the time to develop a disease complication during the 18 
months of follow-up period is significantly faster in those children who have a serologic 
response against at least 1 antigen. There is a difference between the cohort studies 
performed in children and adults indicating differences as to which immune response has the 
greatest effect on the course of the disease in children and adults. The reason for this 
difference is not yet understood. 
Amre et al.[85] also studied a cohort of pediatric CD patients prospectively and they 
found that among ASCA+ patients the occurrence of surgical procedures was higher, and an 
even stronger association was found in the ASCA+/P-ANCA- patient subgroup. Survival 
analysis revealed that the time to first complication (fistula or abscess) was shorter for 
ASCA+ patients than those who were ASCA-, and for P-ANCA- patients than P-ANCA+ 
patients. 
Secondly, important confounding factors were not tested in many of the previous cross-
sectional serology studies; however influence disease phenotype (eg. disease duration and 
smoking habit). And the association between serological markers and disease phenotype was 
not corrected for these factors. Correcting phenotype-serotype associations with disease 
duration when multiple factors are included in the analysis can reveal that some of them are 
rather time-dependent variables and are not associated with the serological profile per se.  
Thirdly, one could query whether a complication leads to an alteration in mucosal 
permeability and hence seroreactivity to microbial antigens. The prevalence and titer of 
ASCA, anti-I2, anti-OmpC, and also the presence of multiple serologic responses were more 
frequent after longer disease duration in previous studies [16, 82]. In our Hungarian CD 
cohort [32] only ACCA and anti-OmpC response, but not other anti-glycans including 
ASCA, was positively associated with disease duration. Similarly, the presence of ASCA in 
other cohorts of CD patients were also relatively constant during the course of the disease 
[76,77]. These observations and the finding that ASCA antibodies may appear before the 
diagnosis of CD and may predict the development of IBD [73] further support the importance 
of prospective longitudinal studies using serological markers.  
One should be also aware of the fact that really striking differences in serologic response 
are demonstrated only in a minority of patients. About 1/4 of the patients are positive for 
several antibodies and have markedly elevated antibody titers at the same time. The 
proportion of seronegative patients, or patients being positive for only 1 antigen with low 
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antibody titer, is about the same. The remaining 50% of all CD patients have an intermediate 
phenotype based on the serologic assessments. The aim is to find new serologic markers with 
which we shall be able to identify certain homogenous groups of patients in this “grey zone” 
regarding disease progression and response to therapy. 
 
 
Serologic Markers in the Follow-Up and Treatment of IBD 
 
In patients with UC, no correlation was found between the presence and titer of atypical 
P-ANCA and the activity of the disease. The titer of atypical P-ANCA remains unchanged 
even after a colectomy [86,87]. Similarly, the presence of ASCA seems to be independent 
from the disease activity[76, 77]. As a consequence, neither atypical P-ANCA, nor ASCA is 
suitable for monitoring of the disease. 
Landers et al. found that following anti-TNF-α treatment the prevalence and titer of the 
various antibodies (ASCA, atypical P-ANCA, anti-I2 and anti-OmpC) remained unchanged 
in the majority of patients [33]. Mesalazine treatment also leaves the ASCA level unchanged 
in active CD patients [88]. ASCA positivity remains even after steroid treatment, but the 
antibody titer decreases [89]. 
The role of the serologic response in the prediction of therapeutical effectiveness is yet to 
be determined. A Belgian study involving 279 CD patients failed to find any correlation 
between the atypical P-ANCA or ASCA positivity and the rate of response of patients given 
anti-TNF-α treatment. The investigators observed a generally poorer responsiveness in the 
case of atypical P-ANCA+/ASCA- status, but the difference was not significant [90]. 
Similarly, significantly lower early clinical response (55% vs. 76% OR 0.4 (95%CI 0.16-
0.99), p=0.049) were reported in ANCA+/ASCA- UC patients after infliximab treatment by 
the same group [91]. 
Patients exhibiting serologic responses directed against various microbial antigens 
(OmpC and I2) should expect a higher remission rate if the budesonide treatment was 
supplemented by ciprofloxacin and metronidazole, while in anti-OmpC/I2 seronegative group 
budesonide treatment alone proved to be more effective [92]. The study brings up the 
possibility that certain antibiotics are more effectively used in those CD patients who present 
a marked immunologic response against microbial antigens. This group of patients may be 
the one that can be most effectively treated by manipulating the bacterial flora. 
 
 
Mutations of the Serologic Markers and  
Receptors Taking Part in Innate Immunity 
 
The real importance of the antibodies produced against various microbial and 
autoantigens may yet to be discovered. Increasing amount of evidence suggests that the 
hyperresponsive adaptive immunologic response to microbial antigens found in patients with 
CD is a reflection of the underlying immunopathogenesis of this disorder. Whether this 
adaptive immunologic response is reflective of acquired characteristics or has an underlying 
genetically determined influence is an important question. Supporting the latter possibility is 
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the observation that increased ASCA and anti-OmpC expression, both qualitatively and 
quantitatively, in unaffected relatives of patients with CD[70,71,72]. Recent findings [93] in 
the C3Bir mouse model – a genetic defect in innate immunity accompanying the Cdcs1 allele 
results in a hyperresponsive to bacterial ligands – also suggests this link. In humans, loss-of-
function mutations of the innate immune gene nucleotide-binding oligomerization domain 
(NOD2) could results in the same phenomenon. In most[32, 94, 95] but not all previous 
studies[79, 80, 82] it was revealed that patients with CD carrying a NOD2 variant had a 
higher qualitative and quantitative serologic response than patients carrying no variants. This 
association was independent of the association with ileal involvement and complicated 
disease behavior that have been described for NOD2 variants and antimicrobial antibodies 
respectively. Moreover positive correlation was found between the number of mutations and 
the prevalence of anti-microbial antibodies indicating genetic dosage effect. In the study of 
Devlin et al.[91] unaffected relatives carrying a NOD2 variants had greater serologic 
response to microbial antigens than those carrying no variants further strengthen the above 
mentioned hypothesis. The increased expression of antibodies directed against bacterial and 
yeast antigens is likely a function of increased exposure of the mucosal immune system to a 
range of microbial antigens owing to diminished initial clearance, perhaps due to impaired 
secretion of defensins. Hence, a defect in muramyl dipeptide signaling via NOD2 variants 
could result in impaired defense against microbial species, with the subsequent development 
of antibodies to microbial antigens being a secondary phenomenon due to bacterial invasion 
and increased exposure of the mucosal immune system to a range of microbial antigens [96]. 
Our group found a significant, inverse association between the DEFB1 20A variant and 
positivity of anti-glycan antibodies, irrespective of location or disease behavior [97], but we 
did not find an association between NOD1/CARD4 and any of the glycan markers or 
conventional ASCA antibodies in CD. In contrast, Henckaerts et al.[95] reported that CD 
patients carry at least one GG-indel allele in NOD1/CARD4 had a higher prevalence of 
gASCA antibodies than patients who carry wild type allele. Here also, gene-dosage effect 
was observed. Of note, in our study the E266K variant was investigated. Finally we failed to 
demonstrate an association between the DLG5 R30Q variant and any of the serological 
markers investigated. 
Mannan-binding lectin (MBL) is also a pattern recognition receptor and an important 
component of innate immunity. In the study of Seibold et al. [98], MBL deficiency was 
associated with ASCA positivity not only in patients with CD but also in their relatives. 
Lymphocytes of the patients also showed to proliferate in response to mannan. Thus, it 
appears that MBL deficiency could impair normal processing of mannan-expressing 
microbial antigens, such as those found on the cell surface of many common microorganisms. 
The accumulated antigens could then stimulate the immune system, and contribute to the 
production of ASCA and possibly the pathogenesis of Crohn’s disease [99]. It should be 
noted, however, that a follow-up study, testing a larger cohort of CD patients failed to 
confirm the significant association between variant MBL genotypes and ASCA positivity. 
The observed trend, however, did show that the frequency of ASCA positivity was 
proportional to the relative deficiency of the coding genotype [100]. 
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No association was found between variants in TLR genes and seroreactivity to microbial 
antigens. This is not necessarily surprising because the association between variants in TLR 
genes and IBD has been less consistent than the association between CD and functional 
variants of NOD2 gene[32, 94]. 
 
 
Conclusion 
 
ASCA and atypical P-ANCA remain the best characterized markers in IBD. Unlike 
ASCA assays, which are generally ELISA tests and both simple to run and well-standardized, 
atypical P-ANCA testing is dependent on experienced personnel for both running and 
interpreting the test results. Results of the various assays used for the detection of atypical P-
ANCA may differ significantly from each other and must therefore be compared very 
carefully. Individually ASCA and atypical P-ANCA tests have moderate sensitivity and 
specificity. Atypical P-ANCA and ASCA cannot be used for monitoring, because the 
antibody titers are relatively stable and do not correlate with disease activity. 
Assessing both ASCA and atypical P-ANCA reactivity allows better differentiation of 
CD from UC and from non-CD than using the individual tests alone. The ASCA+/atypical P-
ANCA- phenotype is characteristic of CD, while the ASCA-/atypical P-ANCA+ phenotype is 
seen primarily in UC. Viewed together, the two assays offer a differential diagnostic which 
may be particularly helpful in those cases when the diagnosis of CD or UC cannot be safely 
established using conventional investigation methods (medical history, radiological 
assessments, endoscopy and biopsy). These markers can help in the assessment of about half 
of the patients in the indeterminate colitis (CD or UC) category. However, the presence of 
ASCA and other anti-glycan antibodies in patients with gastrointestinal symptoms may also 
indicate celiac disease. 
In Crohn’s disease ASCA positivity carries a higher chance of a complicated disease 
behavior and the need for early surgical intervention. In UC in the presence of atypical P-
ANCA one can expect a dominantly left-sided disease which is often severe and resistant to 
therapy, and the risk of early surgical intervention is high.  
Newer markers derived from various microbial inhabitants of the gut, such as Omp, I2, 
and CBir1, as well as various glycan markers offer new ways to stratify patients into 
serologic subgroups. The cumulative presence and extent of the serologic response directed 
against these various makers may act as prognostic indicators of the severity and behavior of 
the ileal disease. Patients with CD and unaffected relatives carrying variants of the NOD2 
gene have increased adaptive immune response to microbial antigen supporting an underlying 
genetically determined influence and the importance of altered microbial sensing in the 
pathogenesis of the CD. The role of the antimicrobial antibodies as subclinical markers in 
healthy relatives of IBD patients is yet to be established.  
There is considerable overlap of the reactivity of many of the new serological markers 
and additional studies to more fully understand the basis for their development as well as 
their clinical significance are required. Addition of these, as well as yet to be discovered new 
markers, to the serologic IBD diagnostic algorithm will likely result in incremental increases 
in sensitivity. Increases in sensitivity however, can often be accompanied by reductions in 
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specificity and this outcome must be carefully assessed and recognized. Evolution of 
effective serological test panels will involve sifting through the various markers to arrive at 
optimal diagnostic utility balanced with practical economic realities.  
We have made significant progress in understanding the clinical features associated with 
various serologic markers in IBD. The on-going challenge is how to best utilize these new 
assays to provide clinically relevant information in a cost-effective manner. Assembly of 
logical panels of serologic markers to identify patients who are at a predicted increased risk 
of more severe disease and who may benefit from and early intensive monitoring and therapy 
to improve long-term outcome is a primary practical goal. Further prospective clinical trials 
will be needed to determine the evolving role and practical clinical importance of serologic 
assessments in IBD. 
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